{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:46Z","timestamp":1772165626299,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04417-6","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:36:12Z","timestamp":1764074172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance"],"prefix":"10.1186","volume":"25","author":[{"given":"R.","family":"Dertli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"As\u0131l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Atayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Co\u015far","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Yola\u00e7an","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"B\u0131y\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"4417_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/jgh.14456","volume":"34","author":"S Sue","year":"2019","unstructured":"Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34:686\u201392.","journal-title":"J Gastroenterol Hepatol."},{"key":"4417_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5009\/gnl20330","volume":"16","author":"JM Liou","year":"2022","unstructured":"Liou JM, Lee YC, Wu MS, Taiwan Gastrointestinal disease and Helicobacter Consortium. Treatment of refractory Helicobacter pylori infection-tailored or empirical therapy. Gut Liver. 2022;16:8\u201318.","journal-title":"Gut Liver"},{"issue":"2","key":"4417_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3748\/wjg.v29.i2.390","volume":"29","author":"YM Monteiro","year":"2023","unstructured":"Pedro Vieira de Moraes Andrade, Monteiro YM. Ethel Zimberg Chehter. Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review. World J Gastroenterol. 2023;29(2):390\u2013409.","journal-title":"World J Gastroenterol"},{"key":"4417_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/apt.14561","volume":"47","author":"M Zamani","year":"2018","unstructured":"Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"4417_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1056\/NEJMra020542","volume":"347","author":"S Suerbaum","year":"2002","unstructured":"Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175\u201386.","journal-title":"N Engl J Med"},{"key":"4417_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/MCG.0b013e318030e3c3","volume":"41","author":"DA Di Makola","year":"2007","unstructured":"Di Makola DA, Crowe SE. Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol. 2007;41:548\u201358.","journal-title":"J Clin Gastroenterol"},{"key":"4417_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","journal-title":"Gut"},{"key":"4417_CR8","doi-asserted-by":"publisher","first-page":"e5114","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:e5114\u20136914.","journal-title":"Gastroenterology"},{"key":"4417_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/14656566.2020.1845649","volume":"22","author":"S Georgopoulos","year":"2021","unstructured":"Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22:729\u201341. https:\/\/doi.org\/10.1080\/14656566.2020.1845649.","journal-title":"Expert Opin Pharmacother"},{"key":"4417_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12916-024-03816-y","volume":"22","author":"AS-NA Nabavi-Rad","year":"2024","unstructured":"Nabavi-Rad AS-NA. Tanya Marie Monaghan. Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis. BMC Med. 2024;22:598.","journal-title":"BMC Med"},{"key":"4417_CR11","doi-asserted-by":"publisher","unstructured":"Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut 2022 Aug 8:gutjnl-2022-327745. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745","DOI":"10.1136\/gutjnl-2022-327745"},{"issue":"7","key":"4417_CR12","first-page":"410","volume":"36","author":"Z Liu","year":"2025","unstructured":"Hongxiu Yu1, Zhengwen Zhou2, Liu Z. First-line eradication of Helicobacter pylori infection with High-Dose amoxicillin and vonoprazan: A systematic review and Meta-analysis. Turk J Gastroenterol. 2025;36(7):410\u20139.","journal-title":"Turk J Gastroenterol"},{"issue":"3","key":"4417_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1089\/mdr.2022.0146","volume":"29","author":"M Aya\u015f","year":"2023","unstructured":"Aya\u015f M, G\u00fcrol Y. Antibiotic resistance of Helicobacter pylori in Turkey: a systematic review and meta-analysis. Microb Drug Resist. 2023;29(3):96\u2013103.","journal-title":"Microb Drug Resist"},{"key":"4417_CR14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3748\/wjg.v10.i11.1656","volume":"10","author":"E Altintas","year":"2004","unstructured":"Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol. 2004;10:1656\u20138.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4417_CR15","first-page":"29","volume":"16","author":"S G\u00fcliter","year":"2005","unstructured":"G\u00fcliter S, Kele\u015f H, \u00d6zkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of Helicobacter pylori? Turk J Gastroenterol. 2005;16(1):29\u201333.","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"4417_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1523-5378.2009.00735.x","volume":"15","author":"BH Lee","year":"2010","unstructured":"Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010;15(1):38\u201345.","journal-title":"Helicobacter"},{"issue":"4","key":"4417_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1751-2980.2010.00445.x","volume":"11","author":"CS Qua","year":"2010","unstructured":"Qua CS, Manikam J, Goh KL. Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on? J Dig Dis. 2010;11(4):244\u20138.","journal-title":"J Dig Dis"},{"issue":"9","key":"4417_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/14787210.2018.1511427","volume":"16","author":"DY Graham","year":"2018","unstructured":"Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple radication therapies. Expert Rev Antiinfect Ther. 2018;16(9):679\u201387.","journal-title":"Expert Rev Antiinfect Ther"},{"issue":"4","key":"4417_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12989","volume":"28","author":"R Zeng","year":"2023","unstructured":"Zeng R, Li X, Wang F, Xie J, Song C, Xie Y. Reinforced medication adherence improves Helicobacter pylori eradication rate in developing countries: a systematic review and meta-analysis of randomized controlled trials. Helicobacter. 2023;28(4):e12989.","journal-title":"Helicobacter"},{"issue":"4","key":"4417_CR20","doi-asserted-by":"publisher","first-page":"e12989","DOI":"10.1111\/hel.12989","volume":"28","author":"X Chen","year":"2023","unstructured":"Chen X, Zhou Y, Wang Q, et al. Effectiveness of reinforced education on Helicobacter pylori eradication adherence: A meta-analysis of randomized trials in developing countries. Helicobacter. 2023;28(4):e12989.","journal-title":"Helicobacter."},{"issue":"6","key":"4417_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ueg2.12569","volume":"12","author":"21HJM Ferrer-Barcel\u00f3","year":"2024","unstructured":"Ferrer-Barcel\u00f3 21HJM, Su\u00e1rez L, Barcelo-Cerda P, Sempere S, et al. J., l; Hp-EuReg Investigators. Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(6):691\u2013704.","journal-title":"United European Gastroenterol J."},{"key":"4417_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/2050640615618043","volume":"4","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United Eur Gastroenterol J. 2016;4:380\u20137.","journal-title":"United Eur Gastroenterol J"},{"key":"4417_CR23","doi-asserted-by":"publisher","unstructured":"Saito Y, Konno K, Sato M, at al. Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant helicobacter pylori. Cancers (Basel). 2019;11(1):116. https:\/\/doi.org\/10.3390\/cancers11010116.","DOI":"10.3390\/cancers11010116"},{"key":"4417_CR24","doi-asserted-by":"publisher","unstructured":"Ribaldone DG, Fagoonee S, Astegiano M, et al. Rifabutin-based rescue therapy for helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients. J Clin Med. 2019;8(2):199. https:\/\/doi.org\/10.3390\/jcm8020199.","DOI":"10.3390\/jcm8020199"},{"key":"4417_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6523653","volume":"2018","author":"JH Choi","year":"2018","unstructured":"Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current status of the third-line Helicobacter pylori eradication. Gastroenterol Res Pract. 2018;2018:6523653.","journal-title":"Gastroenterol Res Pract"},{"issue":"12","key":"4417_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/1751-2980.12559","volume":"18","author":"JF Ye","year":"2017","unstructured":"Ye JF, Hong JB, Zhu Y, et al. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. J Dig Dis. 2017;18(12):704\u20138.","journal-title":"J Dig Dis."},{"key":"4417_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-023-00539-y","volume":"15","author":"DW Shin","year":"2023","unstructured":"Shin DW, Cheung DY, Song JH, et al. The benefit of the bismuth add-on to the 2-week clarithromycin-based triple regimen for Helicobacter pylori eradication: a propensity score-matched retrospective study. Gut Pathog. 2023;15:13.","journal-title":"Gut Pathog"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04417-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04417-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04417-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:36:13Z","timestamp":1764074173000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04417-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4417"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04417-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7616078\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in compliance with the current version of the Declaration of Helsinki and the good clinical practice guidelines. Written informed consent was obtained from all participating patients, and all personal information was kept confidential. This study received ethics approval from Ethics Committee of NE\u00dc Faculty of Medicine (approval number: 2025\/5489).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"833"}}